```html

Quasi‑Stroke Syndrome: A Comprehensive Medical Guide

Overview

Quasi‑Stroke Syndrome (QSS)—sometimes called “stroke mimic” or “stroke‑like syndrome”—is a collection of neurological events that closely resemble an acute ischemic or hemorrhagic stroke but arise from non‑vascular causes. Patients present with sudden weakness, speech difficulty, visual changes, or sensory loss, yet imaging typically shows no definitive occlusion or bleeding.

QSS can affect anyone, but the highest incidence is reported in:

• Adults aged 45‑80 years (≈ 70 % of cases)
• Individuals with a history of migraine, epilepsy, or metabolic disorders
• Patients taking certain medications (e.g., anticonvulsants, anti‑migraine agents)

Exact prevalence is difficult to pin down because many cases are initially misdiagnosed as true strokes. Large emergency‑department studies estimate that 8‑12 % of patients activated for stroke alerts ultimately receive a diagnosis of a stroke mimic, and QSS accounts for roughly 30‑40 % of those mimics (Mayo Clinic Proceedings, 2022).

Symptoms

The clinical picture mirrors that of an actual stroke. The following list includes the most frequently reported symptoms, each with a brief description.

• Sudden unilateral weakness or numbness – often affecting the face, arm, or leg on one side.
• Facial droop – difficulty smiling or closing the eye on the affected side.
• Speech disturbances – slurred speech (dysarthria) or difficulty finding words (expressive aphasia).
• Visual field deficits – loss of vision in one half of the visual field (homonymous hemianopia) or double vision.
• Ataxia – loss of coordination, leading to stumbling or difficulty with fine motor tasks.
• Dizziness or vertigo – sensation of spinning or imbalance, sometimes accompanied by nausea.
• Headache – often throbbing, can be migrainous in nature.
• Seizure activity – focal seizures may precede or accompany the neurological deficits.
• Altered consciousness – ranging from mild confusion to transient loss of awareness.
• Transient sensory disturbances – tingling or “pins‑and‑needles” sensations that may wax and wane.

Symptoms typically develop abruptly, reach a peak within minutes, and may improve partially or completely within hours to days—an evolution that helps differentiate QSS from most true strokes, which usually progress or stabilize.

Causes and Risk Factors

QSS does not stem from an actual blockage or bleed in the brain’s blood vessels. Instead, several pathophysiological mechanisms can trigger stroke‑like presentations.

Primary Causes

• Hemiplegic migraine – a rare migraine subtype that produces temporary hemiparesis and aura.
• Seizure‑related post‑ictal paralysis (Todd’s paresis) – transient weakness following a focal seizure.
• Metabolic disturbances – severe hypoglycemia, hyperosmolar states, or electrolyte imbalances (e.g., hyponatremia).
• Medication toxicity – especially with antiepileptic drugs (e.g., phenytoin, carbamazepine) and immunosuppressants.
• Infectious encephalitis – early stages can mimic stroke before classic infectious signs appear.
• Structural brain lesions – demyelinating plaques (multiple sclerosis), tumors, or cavernous malformations that acutely irritate cortical tissue.
• Functional (psychogenic) neurological disorder – rarely, conversion disorder can produce stroke‑like deficits.

Risk Factors

• History of migraine with aura (especially hemiplegic migraine)
• Chronic epilepsy or recent seizure activity
• Uncontrolled diabetes or episodes of severe hypoglycemia
• Renal or hepatic failure leading to metabolic encephalopathy
• Use of CNS‑active medications (antiepileptics, certain antidepressants)
• Recent head trauma or neurosurgery
• Autoimmune diseases (e.g., systemic lupus erythematosus) that predispose to cerebral vasculitis

Diagnosis

Because QSS mimics stroke, the initial work‑up follows the same rapid “stroke‑code” pathway to rule out life‑threatening vascular events.

Step‑by‑Step Diagnostic Approach

1. Immediate clinical assessment – NIH Stroke Scale (NIHSS) is applied to quantify deficits.
2. Non‑contrast CT head – performed within 25 minutes of arrival to exclude hemorrhage.
3. CT angiography (CTA) or MR angiography (MRA) – evaluates for large‑vessel occlusion.
4. Diffusion‑weighted MRI (DW‑MRI) – the most sensitive test; a true ischemic stroke shows restricted diffusion, whereas QSS often does not.
5. Laboratory panel – glucose, electrolytes, renal & liver function, complete blood count, coagulation profile, and toxicology screen.
6. Electroencephalogram (EEG) – indicated when seizure‑related causes are suspected.
7. Lumbar puncture – reserved for suspected infectious or inflammatory causes when imaging is inconclusive.
8. Specialized testing – serum lactate, ammonia, or autoimmune panels (ANA, anti‑dsDNA) if metabolic or autoimmune etiologies are high on the differential.

A diagnosis of QSS is made when:

• Neuroimaging shows no acute infarct or bleed that explains the deficits.
• Laboratory or electrophysiological data point to an alternative non‑vascular cause.
• The clinical course is rapidly reversible (often within 24 hours) without reperfusion therapy.

Treatment Options

Treatment is directed at the underlying trigger rather than at a clot or bleed. Prompt identification is essential to avoid unnecessary thrombolysis.

Acute Management

• Stabilize blood glucose – administer dextrose for hypoglycemia or insulin for hyperglycemia.
• Seizure control – benzodiazepines (e.g., lorazepam) followed by loading doses of antiepileptics if Todd’s paresis is suspected.
• Reverse toxicity – e.g., charcoal or antidotes for drug overdoses.
• Intravenous fluids – correct dehydration, hyponatremia, or hyperosmolar states.
• Targeted migraine therapy – triptans are contraindicated in true stroke; for hemiplegic migraine, consider IV magnesium, anti‑emetics, and supportive care.

Long‑Term Therapies

• Medication adjustments – review and potentially taper neuroactive drugs that precipitate QSS.
• Antiepileptic optimization – choose agents with lower neurotoxic profiles (e.g., levetiracetam).
• Management of chronic conditions – tight glycemic control, renal/hepatic monitoring, and blood pressure regulation.
• Preventive migraine strategies – beta‑blockers, calcium‑channel blockers, or CGRP monoclonal antibodies for patients with frequent hemiplegic migraines.
• Rehabilitation – physical, occupational, and speech therapy may be needed if deficits persist beyond 48 hours.

When Thrombolytics Are Considered

If imaging is equivocal and the patient falls within the therapeutic window (< 4.5 hours), many centers proceed with alteplase after a careful risk‑benefit discussion, documenting that the possibility of a stroke mimic exists. Studies show that thrombolysis in correctly identified stroke mimics does not increase bleed risk significantly, but it does expose patients to unnecessary medication (JAMA Neurology, 2021).

Living with Quasi‑Stroke Syndrome

While QSS itself is not permanently disabling, the unpredictable episodes can affect quality of life. Below are practical tips for patients and caregivers.

• Maintain a symptom diary – record timing, triggers, and duration of each episode to help clinicians pinpoint patterns.
• Medication review every 6 months – bring all prescriptions, over‑the‑counter drugs, and supplements to appointments.
• Educate family and coworkers – ensure they recognize that sudden weakness may not be a true stroke but still warrants urgent evaluation.
• Adopt a balanced diet – low in processed sugars and saturated fats, rich in omega‑3 fatty acids, which support neuronal stability.
• Regular physical activity – aerobic exercise improves cerebral perfusion and reduces migraine frequency.
• Stress‑management techniques – mindfulness, yoga, or CBT have demonstrated benefit in lowering migraine and seizure thresholds.
• Sleep hygiene – aim for 7‑9 hours nightly; sleep deprivation is a well‑known trigger for both seizures and migraines.
• Carry a medical alert card – list “Quasi‑Stroke Syndrome” and known triggers; include emergency contact numbers.

Prevention

Because QSS results from modifiable triggers in many cases, prevention focuses on controlling those underlying factors.

• Control diabetes – target HbA1c < 7 % (American Diabetes Association).
• Manage migraine prophylactically – regular use of preventive agents reduces attack frequency by up to 50 % (Cochrane Review, 2020).
• Optimize antiepileptic therapy – keep serum drug levels within therapeutic range.
• Avoid medication interactions – use drug‑interaction checkers when adding new prescriptions.
• Hydration and electrolyte balance – especially in elderly patients on diuretics.
• Regular monitoring for renal and hepatic function – dose‑adjust CNS‑active drugs accordingly.

Complications

If QSS is repeatedly misdiagnosed or left untreated, several complications can arise:

• Unnecessary thrombolysis or anticoagulation – raises bleeding risk without benefit.
• Delayed treatment of the true underlying cause – e.g., untreated hypoglycemia may lead to seizures or permanent neuronal injury.
• Psychological distress – anxiety about “having a stroke” can limit daily activities.
• Functional decline – frequent episodes may lead to deconditioning, especially in older adults.
• Increased healthcare utilization – repeated emergency visits and imaging raise costs and expose patients to radiation.

When to Seek Emergency Care

References

• Mayo Clinic Proceedings. “Stroke Mimics: Frequency, Clinical Features, and Outcomes.” 2022.
• JAMA Neurology. “Outcomes of Thrombolysis in Stroke Mimics.” 2021.
• American Diabetes Association. “Standards of Medical Care in Diabetes—2024.”
• Cochrane Database of Systematic Reviews. “Prophylactic Treatment for Migraine.” 2020.
• National Institute of Neurological Disorders and Stroke (NINDS). “Hemiplegic Migraine.” Updated 2023.
• World Health Organization. “Global Burden of Neurological Disorders.” 2023.

```